Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

OBJECTIVE: Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple-dose study we evaluated the safety and efficacy of dapagliflozin in type 2 diabetic patients. RESEARCH DESIGN AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: List, James F., Woo, Vincent, Morales, Enrique, Tang, Weihua, Fiedorek, Fred T.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660449/
https://www.ncbi.nlm.nih.gov/pubmed/19114612
http://dx.doi.org/10.2337/dc08-1863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660449/
https://www.ncbi.nlm.nih.gov/pubmed/19114612
http://dx.doi.org/10.2337/dc08-1863

Ejemplares similares